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Abstract 
Carcinomatous meningitis due to bladder cancer is a rare entity reported only in case 
reports. Optimal therapy is thus poorly defined with earlier cases reporting an 
unsuccessful outcome. Here we report a case of late carcinomatous meningitis secondary 
to transitional cell carcinoma (TCC) of the bladder occurring in a patient in complete 
remission. He was successfully treated with intrathecal methotrexate and whole brain 
irradiation and experienced prolonged survival after treatment. With modern 
chemotherapy increasing complete remissions and survival rates in patients with TCC, 
more and more patients are being reported with carcinomatous meningitis. We raise the 
question of whether central nervous system prophylaxis should be considered in 
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A 47-year-old white male presented with TCC of the bladder which had metastasized to bone as 
revealed by PET-CT. Chemotherapy with cisplatin and gemcitabine resulted in a radiographic complete 
remission after 7 cycles. Three months after completing chemotherapy, the patient presented with 
headache. A brain MRI suggested carcinomatous meningitis (see fig. 1, fig. 2). He then developed a 
right CN III palsy. A lumbar puncture confirmed the diagnosis (see fig. 3). The patient was treated with 
biweekly intrathecal MTX via an Ommaya reservoir for 6 weeks, resulting in the clearance of his 
cerebrospinal fluid; however, his cranial nerve palsy persisted. He then underwent whole brain 
irradiation (3,960 cGy at 180 cGy per day over 22 days by the ‘German Helmet’ technique) with 
resolution of his cranial nerve palsy. He is currently alive 9 months after his diagnosis of carcinomatous 
meningitis. 
Discussion 
Cancer of the urinary bladder is diagnosed in approximately 70,500 people each year in 
the United States, and about 14,000 individuals die [1]. Central nervous system (CNS) 
involvement is rarely reported. In a study by Anderson et al. [2] involving CNS 
complications occurring in bladder cancer, no patient developed carcinomatous 
meningitis and only 1% of patients developed brain metastasis in a series of 359 patients. 
For carcinomatous meningitis associated with other solid tumors, a typical induction 
regimen consists of a fixed dose of 10 or 12 mg of intrathecal MTX twice weekly for 4 
weeks. If clinical response occurs, the frequency of administration is decreased to once 
weekly for 4–8 weeks; a maintenance regimen is then continued with drug administration 
every 2 weeks for several months, and then monthly for 2–4 months. The optimal 
duration of therapy is unknown [3]. 
The route of delivery of intrathecal chemotherapy may impact outcome. Shapiro et al. 
[4] demonstrated that MTX administration using an Ommaya reservoir more reliably 
produced adequate cerebrospinal fluid distribution than administration by lumbar 
puncture. In another study, 100 patients with clinically and cytologically or 
radiographically documented neoplastic meningitis stemming from solid tumors received 
intracerebrospinal fluid liposomal cytarabine or MTX. Progression-free survival (the 
primary study endpoint) was identical between the sustained-release cytarabine and MTX 
treatment arms for all 100 patients (35 vs. 37.5 days, respectively, p = 0.79). When 
progression-free survival was examined as a function of the route of chemotherapy 
administration (lumbar vs. ventricular), there was no difference for patients treated with 
sustained-release cytarabine (29 vs. 43 days, respectively, p = 0.35). For patients treated 
with MTX, however, there was a statistically significant difference favoring patients 
receiving intraventricular therapy (19 vs. 43 days, respectively, p = 0.048) [5]. Hitchins et 
al. [6] also noted that responses were more frequent if therapy was administered via an 
Ommaya reservoir. We speculate that placing an Ommaya reservoir in our patient may 
have contributed to his relatively prolonged overall survival.  
There are several cases of transitional cell carcinomatous meningitis reported in the 
literature – with our case bringing the total to 30. While some patients presented with 
grossly widespread disease including the CNS, our literature review suggests that many 
patients had the complication occur after successful treatment of their systemic disease 
(see table 1). For example, Bishop et al. [7] reported 2 patients developing disease after 
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Matsushita et al. [8] reported a case occurring 16 months after their patient had had a 
complete response following chemotherapy and surgery, and Boukriche et al. [9] reported 
a case occurring 4 years after adjuvant treatment for resected bladder cancer. Still, just as 
many cases present concurrently with widespread systemic disease, suggesting that TCC 
may have an affinity for the CNS and that carcinomatous meningitis may be more 
common than realized. The prognosis for most patients with carcinomatous meningitis 
secondary to TCC is dismal, with patients surviving a median of 38 days [31]. Our review 
confirms the poor prognosis with an average survival of 2.2 months for all patients in 
which survival has been reported. Interestingly, the average time to the development of 
carcinomatous meningitis is 14 months (see table 1). 
With more cases appearing in the literature, it raises the question: does the successful 
treatment of systemic disease with modern chemotherapy change the natural history of 
the disease? Dhote et al. [33] reported on 50 patients with advanced TCC of the bladder 
treated with MVAC and noted that 8 patients experienced a CNS relapse (16%). In their 
series, brain metastasis occurred within a mean of 21 months. In the series by Bishop et al. 
[6], 2 of 17 patients treated with MVAC had carcinomatous meningitis (12%). Finally, in 
a series reported by Sternberg et al. [34], 2 out of 12 patients achieving complete response 
on MVAC later developed CNS disease (17%). We can only surmise that in the series by 
Anderson et al. [2], in which data was collected on patients between 1962 and 2001, the 
majority of patients did not receive cisplatin-based chemotherapy. With the rising 
incidence of TCC of the bladder, more and more patients are now dying of complications 
seen only in advanced stages of disease. With modern chemotherapy, median survival has 
increased from 3–6 months in the pre-MVAC era to its current figure of almost 1 year. 
This combination chemotherapy, in a multicenter phase III trial, was shown to increase 
median survival from 8.2 to 12.5 months [35]. As with any chemotherapy, MVAC is 
associated with complications like cardiac and renal toxicities, along with neutropenia 
and mucositis. The rate of death due to MVAC toxicity is around 3–4% and the disease-
free survival rate is 3.7% at 6 years [34, 35]. A newer phase III study has shown the clear 
advantage of using the gemcitabine-cisplatin combination as it is as effective as MVAC, 
but with less systemic toxicity [36]. Reports of carcinomatous meningitis occurring when 
the gemcitabine-cisplatin combination is used are increasing, similar to the trend 
reported for MVAC. As more and more cases appear in the literature, it may be 
reasonable to consider CNS prophylaxis in patients who achieve complete remission on 
chemotherapy in a metastatic setting. 
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Disease course and treatment summary     CR  Time to  
CNS disease 
months 
TX CNS  OS after 
CNS disease 
months 
Hust, 1980 [10]  nr  cobalt XRT     nr  5  none  5 
Hust, 1980 [10]  IV   meningitis at presentation    na  0  none  0 
Mandell, 1985 [11]  nr  radiation and cystectomy at diagnosis, cisplatin × 5 
at relapse 
 yes  10  IT  MTX/XRT  nr 
Bishop, 1990 [7]  III  MVAC × 4, meningitis after cycle 4    no  32  IT MTX/XRT  5 
Bishop, 1990 [7]  T4  cystectomy, MVAC × 3, meningitis after cycle 3     no  –  none  4 
Hussien, 1989 [12]  IV  MVAC × 5, PR, progressed in 3 months, phase I 
piritrexim with PR  
 no  9  IT  MTX/XRT  5 
Raghavan, 1991 [13]  nr  cisplatin and radiation for localized disease relapsed in 
16 months, MVAC × 2, IT therapy and 
MVAC × 4 
 yes  16  IT  MTX-O  4 
Eng, 1993 [14]  IV   MVAC × 5, pelvic XRT, PR     no  9  none  0 
Eng, 1993 [14]  IV   cisplatin and MTX with CR, relapsed 2 years later    yes  24  IT MTX/XRT  3 
Steg, 1993 [15]  nr  nr    nr  nr  none  1 
Sugimori, 2005 [16]  IV  presented with meningitis, died of cardiac disease    na  0  none  3 
Imamura, 1997 [17]  IV  presented with meningitis    na  0  none  3 
Bloch, 1987 [18]  IV   surgery for presumed localized disease, brain 
metastasis 2 weeks after surgery, whole body XRT, 
meningitis 3 months later 
 na  3  –  5 
Hasbini, 1997 [19]  T3N2  surgery, MVAC × 4 with CR, meningitis  
1 month later  
 yes  7  –  1 
Santarossa, 1997 [20]  T4N3  MVAC × 6, presented 8 months later with meningitis    yes  14  IT MTX/XRT  9 
Loizaga, 1998 [21]  I  BCG vaccine, mitomycin B, then developed  
meningitis 
 na  15  CMV  0 
Cozzarini, 1999 [22]  III  MVAC × 2 with no improvement, surgery, 
MVAC × 4, then developed meningitis 
 no  6  IT  MTX  3 
Cozzarini, 1999 [22]  III  MVAC × 3, PR, surgery, MVAC × 2    no  9  IT MTX  1 
Vidal, 2000 [23]  IV  presented with carcinomatous meningitis, 
4 doses IT MTX.  
 na  0  IT  MTX  1 
Vidal, 2000 [23]  IV   presented with panhypopituitarism, later diagnosed 
with meningitis 
 na  1  none  2 
Bruna, 2001 [24]  IV  presented with meningitis, died of infection    na  0  IT MTX  2 
Bodi, 2004 [25]  I  TURBT    na  9  none  1.5 
Matsushita, 2004 [26]  III  MVAC × 3, surgery    yes  16  none  25 
Kim, 2005 [27]  nr  surgery    na  108  none  1 
Goodman, 2009 [28]  IV  taxol/carboplatin/gemcitabine/trastuzumab, surgery    yes  nr  IT MTX-O   1.5 
Butchart, 2010 [29]  II  gemcitabine-cisplatin, XRT    yes  5  none  1 
Bowen, 2010 [30]  nr  surgery, gemcitabine-cisplatin × 4    yes  31  XRT  nr 
Uncu, 2010 [31]  IV  radiation, gemcitabine-cisplatin × 6, relapsed in  
lungs in 22 months, gemcitabine-cisplatin resumed, 
CNS disease 2 months later 
 yes  36  IT  MTX/XRT  2 
Zada, 2010 [32]  IV  nr    nr  nr  nr  nr 














CR = Complete remission; Dx = diagnosis; IT = intrathecal; MTX = methotrexate; MVAC = methotrexate, vinblastine, doxorubicin, and cisplatin;
na = not applicable; nr = not reported; OS = overall survival; PR = partial remission; TURBT = transurethral resection of bladder tumor; Tx = 
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Fig. 1. T1-weighted gadolinium-enhanced MRI showing abnormal leptomeningeal enhancement 




Fig. 2. T1-weighted gadolinium-enhanced MRI showing left cerebellar encephalomalacia consistent 
with an old infarct of the left posterior inferior cerebellar artery. 
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Fig. 3. Cytospin analysis of cerebrospinal fluid reveals numerous malignant cells with features 
consistent with metastatic high-grade TCC including large, atypical cells with increased nuclear size, 
prominent nucleoli, and irregular nuclear contours (a–c). Clusters of atypical cells with a papillary 
configuration are also identified (d). (HE ×400). 
 
References 
1  Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300. 
2  Anderson TS, Regine WF, Kryscio R, et al: Neurologic complications of bladder carcinoma: a review of 359 
cases. Cancer 2003;97:2267–2272. 
3  DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998;38:245. 
4  Shapiro WR, Young DF, Mehta BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, 
ventricular and lumbar injections. N Engl J Med 1975;293:161–166. 
5  Glantz MJ, Van Horn A, Fisher R, et al: Route of intracerebrospinal fluid chemotherapy administration and 
efficacy of therapy in neoplastic meningitis. Cancer 2010;116:1947–1952. 
6  Hitchins RN, Bell DR, Woods RL, et al: A prospective randomized trial of single-agent versus combination 
chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5:1655. 
7  Bishop JR Jr, Moul JW, Maldonado L, et al: Transitional cell carcinomatous meningitis after M-VAC 
(methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. Urology 1990;36:373–377. 
8  Matsushita M, Kawasaki Y, Okada Y: Carcinomatous meningitis from urothelial carcinoma of bladder and 
ureter: case report. Nippon Hinyokika Gakkai Zasshi 2004;95:817–819. 
9  Boukriche Y, Bouccara D, Cyna-Gorse F, et al: Sudden bilateral hearing loss disclosing meningeal 
carcinomatosis. Rev Neurol (Paris) 2002;158:728–730. 
10  Hust MH, Pfitzer P: Cerebrospinal fluid and metastasis of transitional cell carcinoma of the bladder. Acta Cytol 
1980;26:217–223. 
11  Mandell S, Wernz J, Morales P, et al: Carcinomatous meningitis from transitional cell carcinoma of bladder. 
Urology 1995;25:520–521. 
12  Hussein AM, Savaraj N, Feun LG, et al: Carcinomatous meningitis from transitional cell carcinoma of the 
bladder: case report. J Neurooncol 1989;7:255–260. Case Rep Oncol 2011;4:406–412 
DOI: 10.1159/000331263 
Published online: 
August 24, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 





13  Raghavan D, Chye RWM: Treatment of carcinomatous meningitis from transitional cell carcinoma of the 
bladder. Br J Urology 1991;67:438–440. 
14  Eng C, Cunningham D, Quade BJ, et al: Meningeal carcinomatosis from transitional cell carcinoma of the 
bladder. Cancer 1993;72:553–557. 
15  Steg R, Frank AR, Lefkowitz DM: Complex partial status epilepticus in a patient with dural metastases. 
Neurology 1993;43:2389–2392. 
16  Sugimori K, Kobayashi K, Hayashi M, et al: Leptomeningeal carcinomatosis from urinary bladder 
adenocarcinoma: a clinicopathological case study. Neuropathology 2005;25:89–94. 
17  Imamura M, Imamura S: Clinicopathologic study of leptomeningeal carcinomatosis involving the temporal 
bone. Ann Otol Rhinol Laryngol 1997;106:674–679. 
18  Bloch JL, Nieh PT, Walzak MP: Brain metastases from transitional cell carcinoma. J Urol 1987;137:97–99. 
19  Hasbini A, Himberlin C, Beguinot I, et al: La méningite carcinomateuse: une complication rare du cancer de la 
vessie. Rev Méd Interne 1997;18:402–406. 
20  Santarossa S, Vaccher E, Balestreri L, et al: Solitary meningeal recurrence in a patient with transitional cell 
carcinoma of the bladder with locally bulky disease at presentation. J Neurooncol 1997;35:141–143. 
21  Loizaga A, Arciniega J, Infante R, et al: Carcinomatosis meníngea en un tumor vesical. Actas Urol Esp 
1999;23:873–875. 
22  Cozzarini C, Reni M, Mangili F, et al: Meningeal carcinomatosis from transitional cell carcinoma of the 
bladder: report of two cases and review of the literature. Cancer Invest 1999;17:402–407. 
23  Vidal OJ, De Paz L, Catalá J, et al: Carcinomatosis meníngea como primera manifestación del carcinoma de 
vejiga: a propósito de dos casos. An Med Interna 2000;17:425–428. 
24  Bruna J, Rojas-Marcos I, Martínez-Yelamos S, et al: Meningeal carcinomatosis as the first manifestation of a 
transitional cell carcinoma of the bladder. J Neurooncol 2003;63:63–67. 
25  Bodi I, Andrews TC, Howard RS, et al: Carcinomatous meningitis from primary signet ring cell carcinoma of 
bladder. Histopathology 2004;44:394–396. 
26  Matsushita M, Kawasaki Y, Okada Y: Carcinomatous meningitis from urothelial carcinoma of bladder and 
ureter: case report. Nippon Hinyokika Gakkai Zasshi 2004;95:817–819. 
27  Kim P, Ashton D, Pollard JD: Isolated hypoglycorrachia: leptomeningeal carcinomatosis causing subacute 
confusion. J Clin Neurosci 2005;12:841–843. 
28  Goodman OB, Milowsky MI, Kaplan J, et al: Carcinomatous meningitis in a patient with Her2/neu expressing 
bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature. J Med Case 
Reports 2009;3:9110. 
29  Butchart C, Dahle-Smith A, Bissett D, et al: Isolated meningeal recurrence of transitional cell carcinoma of the 
bladder. Case Rep Oncol 2010;3:171–175. 
30  Bowen CD, Von Burton G, Bargen RC, et al: Carcinomatous meningitis secondary to transitional cell bladder 
cancer. South Med J 2010;103:809–812. 
31  Uncu D, Arpaci F, Beyzadeoglu M, et al: Meningeal carcinomatosis: an extremely rare involvement of urinary 
bladder carcinoma. Tumori 2010;96:352–354. 
32  Zada G, Chen T: A novel method for administering intrathecal chemotherapy in patients with leptomeningeal 
metastases and shunted hydrocephalus: case report. Neurosurgery 2010;67(3 Suppl Operative):onsE306–
onsE307, discussion onsE307. 
33  Dhote R, Beuzeboc P, Thiounn N, et al: High incidence of brain metastases in patients treated with an M-VAC 
regimen for advanced bladder cancer. Eur Urol 1998;33:392–395. 
34  Sternberg C, Yagoda A, Scher H, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin 
and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403–407. 
35  Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with 
methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative 
group study. J Clin Oncol 1992;10:1066–1073. 
36  von der Maase H, Hansen SW, Roberts JT, Dogliotti L, et al: Gemcitabine and cisplatin versus methotrexate, 
vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, 
multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068. 